Eli Lilly said will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, amid a White House push to ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

"Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal" was originally created and published by Pharmaceutical ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Novo Nordisk ’s oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Eli Lilly’s new weight-loss daily pill underperformed against competitors in weight... The Competition and Consumer ...